Is the Patient a Candidate for Liver Transplantation?

Clinics in Liver Disease

Volumn 16, Issue 2, 2012, Pages 435-448

  Fox, Alyson N ^a,b   Brown, Robert S ^a,c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

Hepatic decompensation; Liver disease; Liver failure; Transplant evaluation; Transplantation

Indexed keywords

ALBUMIN; BILIRUBIN; ELECTROLYTE; PROSTATE SPECIFIC ANTIGEN;

ALBUMIN BLOOD LEVEL; ALCOHOL LIVER DISEASE; ARTERIAL GAS; ARTERY CATHETERIZATION; ASCITES; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BLOOD GROUP TYPING; BONE DENSITY; BONE SCINTISCANNING; CHOLANGITIS; CHOLESTASIS; CLINICAL EVALUATION; CLINICAL PROTOCOL; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CRITERION VARIABLE; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROLYTE BLOOD LEVEL; END STAGE LIVER DISEASE; EXERCISE TEST; FULMINANT HEPATIC FAILURE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HEPATOPULMONARY SYNDROME; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; LUNG FUNCTION TEST; MAMMOGRAPHY; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NEUROIMAGING; PAPANICOLAOU TEST; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PROGNOSIS; PROTHROMBIN TIME; PRURITUS; PSYCHOLOGIC TEST; RATING SCALE; REVIEW; RISK ASSESSMENT; SEROLOGY; SURVIVAL RATE; THORAX RADIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULIN TEST; VASCULAR DISEASE;

CHRONIC DISEASE; END STAGE LIVER DISEASE; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

EID: 84860280835     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.03.014     Document Type: Review

References (52)

1. Based on OPTN data as of October 7. Available at: . Accessed October 7, 2011. http://optn.transplant.hrsa.gov.
2. Ahmed A., Keeffe E.B. Current indications and contraindications for liver transplantation. Clin Liver Dis 2007, 11(2):227-247.
3. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60(8):646-649.
4. Malinchoc M., Kamath P.S., Gordon F.D., et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31(4):864-871.
5. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33(2):464-470.
6. Hanto D.W., Fishbein T.M., Pinson C.W., et al. Liver and intestine transplantation: summary analysis, 1994-2003. Am J Transplant 2005, 5(4 Pt 2):916-933.
7. Martin A.P., Bartels M., Hauss J., et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc 2007, 39(10):3169-3174.
8. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006, 44(1):217-231.
9. Wiesner R., Edwards E., Freeman R., et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124(1):91-96.
10. Merion R.M., Schaubel D.E., Dykstra D.M., et al. The survival benefit of liver transplantation. Am J Transplant 2005, 5(2):307-313.
11. Lucey M.R., Brown K.A., Everson G.T., et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997, 3(6):628-637.
12. Olthoff K.M., Brown R.S., Delmonico F.L., et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl 2004, 10(10 Suppl 2):A6-A22.
13. Murray K.F., Carithers R.L. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005, 41(6):1407-1432.
14. O'Leary J.G., Lepe R., Davis G.L. Indications for liver transplantation. Gastroenterology 2008, 134:1764-1776.
15. Garcia-Retortillo M., Forns X., Feliu A., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35(3):680-687.
16. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122(4):889-896.
17. Berenguer M., Ferrell L., Watson J., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32(4):673-684.
18. Everson G.T., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42(2):255-262.
19. Kim W.R., Poterucha J.J., Kremers W.K., et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10(8):968-974.
20. Everhart J.E., Beresford T.P. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg 1997, 3(3):220-226.
21. Lim J.K., Keeffe E.B. Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. Liver Transpl 2004, 10(10 Suppl 2):S31-S38.
22. Dickson E.R., Grambsch P.M., Fleming T.R., et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989, 10(1):1-7.
23. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001, 33(1):22-27.
24. Kim W.R., Therneau T.M., Wiesner R.H., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000, 75(7):688-694.
25. Soetikno R.M., Lin O.S., Heidenreich P.A., et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56(1):48-54.
26. Kemmer N., Kaiser T., Zacharias V., et al. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008, 40(5):1492-1494.
27. Kowdley K.V., Brandhagen D.J., Gish R.G., et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005, 129(2):494-503.
28. Brandhagen D.J., Alvarez W., Therneau T.M., et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 2000, 31(2):456-460.
29. Tung B.Y., Farrell F.J., McCashland T.M., et al. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl Surg 1999, 5(5):369-374.
30. Medici V., Mirante V.G., Fassati L.R., et al. Liver transplantation for Wilson's disease: the burden of neurological and psychiatric disorders. Liver Transpl 2005, 11(9):1056-1063.
31. Charlton M.R., Burns J.M., Pedersen R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141(4):1249-1253.
32. Schramm C., Bubenheim M., Adam R., et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl 2010, 16(4):461-469.
33. Vogel A., Heinrich E., Bahr M.J., et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004, 18(1):62-69.
34. Prados E., Cuervas-Mons V., de la Mata M., et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998, 66(12):1645-1650.
35. Ratziu V., Samuel D., Sebagh M., et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999, 30(1):131-141.
36. Cruz E., Ascher N.L., Roberts J.P., et al. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome. Clin Transplant 2005, 19(4):501-506.
37. Chinnakotla S., Klintmalm G.B., Kim P., et al. Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation 2011, 92(3):341-345.
38. Larson A.M., Polson J., Fontana R.J., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42(6):1364-1372.
39. O'Grady J.G., Alexander G.J., Hayllar K.M., et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989, 97(2):439-445.
40. Katoonizadeh A., Decaestecker J., Wilmer A., et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int 2007, 27(3):329-334.
41. Schmidt L.E., Larsen F.S. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007, 45(3):789-796.
42. Bernuau J., Goudeau A., Poynard T., et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986, 6(4):648-651.
43. Ascher N.L., Lake J.R., Emond J.C., et al. Liver transplantation for fulminant hepatic failure. Arch Surg 1993, 128(6):677-682.
44. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11):693-699.
45. Freeman R.B., Steffick D.E., Guidinger M.K., et al. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008, 8(4 Pt 2):958-976.
46. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33(6):1394-1403.
47. Yao F.Y., Hirose R., LaBerge J.M., et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005, 11(12):1505-1514.
48. Goldstein R.M., Stone M., Tillery G.W., et al. Is liver transplantation indicated for cholangiocarcinoma?. Am J Surg 1993, 166(6):768-771. [discussion: 71-2].
49. Rea D.J., Heimbach J.K., Rosen C.B., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242(3):451-458. [discussion: 8-61].
50. Watt K.D., Pedersen R.A., Kremers W.K., et al. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009, 137(6):2010-2017.
51. Nair S., Verma S., Thuluvath P.J. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002, 35(1):105-109.
52. Kemmer N.M., Sherman K.E. Liver transplantation trends in the HIV population. Dig Dis Sci 2011, 56(11):3393-3398.